MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Oral curcumin in elective abdominal aortic aneurysm repair: a multicentre randomized controlled trial

Amit X Garg, P J Devereaux, Andrew Hill, Manish Sood, Bharat Aggarwal, Luc Dubois, Swapnil Hiremath, Randolph Guzman, Vikram Iyer, Matthew James, Eric McArthur, Louise Moist, George Ouellet, Chirag R Parikh, Virginia Schumann, Sumit Sharan, Heather Thiessen-Philbrook, Sheldon Tobe, Ron Wald, Michael Walsh, Matthew Weir, Neesh Pannu
CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne 2018 October 29, 190 (43): E1273-E1280
30373740

BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a single-centre randomized human trial. We sought to test whether perioperative oral curcumin (compared with placebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans.

METHODS: We conducted a parallel-group, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 bio markers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N -terminal pro-B-type natriuretic peptide and plasma high-sensitivity C-reactive protein).

RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers ( p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9).

INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media.

TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01225094.

Comments

You need to log in or sign up for an account to be able to comment.

COMET Library wrote:

1

An interesting paper, which had some great discussion in our Critical Appraisal session. Curcumin is a popular herbal suppliment at the moment, and this randomized trial, show no beneficial effect and did show a higher risk of AKI as a secondary outcome.

Trending on Read

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30373740
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"